Future perspectives on immunotherapy for hepatocellular carcinoma.

Area of Science:

• Hepatocellular Carcinoma Research
• Immunotherapy
• Oncology

Background:

• Immune checkpoint inhibitors (ICIs) combinations are now the standard of care for advanced hepatocellular carcinoma (HCC), outperforming multi-kinase inhibitors.
• Research is expanding immunotherapy use to neoadjuvant/adjuvant settings, patients with decompensated liver function, and those awaiting liver transplantation.

Purpose of the Study:

• To review the current landscape and future directions of immunotherapy for hepatocellular carcinoma.
• To highlight emerging indications, novel combination strategies, and new immunotherapeutic agents for HCC.

Main Methods:

• Review of global phase III trials and ongoing investigations into immunotherapy for HCC.
• Analysis of strategies to overcome immunotherapy resistance and enhance tumor immunogenicity.
• Exploration of novel immunotherapeutic agents in early development for HCC.

Main Results:

• ICI combinations demonstrate superior efficacy and survival in advanced HCC.
• Combining immunotherapy with transarterial chemoembolization or radiation shows promise for enhancing tumor immunogenicity.
• Novel agents like triplet therapy, bispecific antibodies, adoptive T-cell therapy, and cancer vaccines show potential synergistic effects with ICIs.

Conclusions:

• Despite significant progress, immunotherapy resistance remains a challenge in HCC treatment.
• Future directions include expanding ICI use to new settings and developing novel agents and combinations to improve patient outcomes.
• Immunotherapy holds extraordinary potential to transform HCC treatment and management.